Author： Hanson Julien de Leval Xavier Kolh Philippe Supuran Claudiu Pirotte Bernard Dogné Jean-Michel
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.13, Iss.8, 2003-08, pp. : 1173-1188
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
GPIIb/IIIa antagonists: the good, the bad and the not too ugly
Inpharma, Vol. 1, Iss. 1616, 2007-01 ,pp. :
Access to resources
Recommend
Bivalirudin benefit independent of GPIIb-IIIa antagonists
Inpharma, Vol. 1, Iss. 1632, 2008-01 ,pp. :
GPIIb-IIIa antagonists in ACS and renal impairment
Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. :
GPIIb-IIIa antagonists: upstream vs deferred use in acute coronary syndromes
Inpharma, Vol. 1, Iss. 1576, 2007-01 ,pp. :
GPIIb-IIIa antagonists cost effective in acute coronary syndromes
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. :